ARTICLE
8 February 2023

Twenty Attorneys General Challenge The Mailing Of Abortion Medication

SG
Shipman & Goodwin LLP

Contributor

Shipman & Goodwin’s value lies in our commitment -- to our clients, to the profession and to the community. We have one goal: to help our clients achieve their goals. How we accomplish it is simple: we devote our considerable experience and depth of knowledge to understand each client’s unique needs, business and industry, and then we develop solutions to meet those needs. Clients turn to us when they need a trusted advisor. With our invaluable awareness of each client’s challenges, we can counsel them at every step -- to keep their operations running smoothly, help them navigate complex business transactions, position them for future growth, or resolve business disputes. The success of our clients is of primary importance to us and our attorneys invest meaningful time getting to know the client's business and are skilled in the practice areas and industry sectors critical to that success. With more than 175 attorneys in offices throughout Connecticut, New York and in Washington, DC, we serve the needs of
On January 3, 2023, the Dobbs Resource Center featured a news update that the FDA issued guidance that allows retail pharmacies to carry and mail the prescription...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On January 3, 2023, the Dobbs Resource Center featured a news update that the FDA issued guidance that allows retail pharmacies to carry and mail the prescription medication mifepristone pursuant to specific FDA rules. See, Shipman's earlier alert: FDA and Medical Abortions. Prior to the FDA's policy change, mifepristone, an abortion medication, could be dispensed only by clinics, doctors and certain mail-order pharmacies.

In addition, on January 4, 2023, the Dobbs Resource Center featured a news update regarding the U.S. Department of Justice Office of Legal Counsel's ("DOJ's) legal opinion to the U.S. Postal Service that the mailing of mifepristone and misoprostol (a drug used in combination with mifepristone for medical abortions) was legal even if mailed to a jurisdiction that significantly restricts abortion. See, Shipman's earlier alert: Mailing of Abortion Medication.

On February 3, 2023 and in response to the DOJ's legal opinion to the U.S. Postal Service, the attorneys general from the states of Alabama, Alaska, Arkansas, Florida, Georgia, Indiana, Iowa, Kentucky, Louisiana, Mississippi, Montana, North Dakota, Ohio, Oklahoma, South Carolina, South Dakota, Texas, Utah and Virginia, wrote letters to national pharmacy chains (CVS and Walgreens) stating that the opinion written by the DOJ referenced above was legally invalid when it opined that the Comstock Act does not prohibit the mailing of abortion medication. This letter from the aforementioned attorneys general included a warning that state attorneys general and private parties could turn to civil litigation to fulfill their responsibilities to protect the health and safety of women by prohibiting the mailing of abortion medication.

In the meantime, battles are also being waged throughout the country to overturn abortion bans through constitutional means. By way of example, the South Carolina state Supreme Court found that the state's constitution protected the right to abortion, overturning the state's ban. Despite this decision, the South Carolina attorney general was one of the signatories to the letter to CVS and Walgreens. As state legislators reconvene, expect to see battles between those in favor of abortion and those against abortion continue, likely resulting in either stricter bans against or greater protections for the right to an abortion.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More